康弘药业
(002773)
| 流通市值：139.60亿 | | | 总市值：187.36亿 |
| 流通股本：6.85亿 | | | 总股本：9.20亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 3,325,058,811.52 | 2,999,322,489.68 | 3,112,962,184.64 | 4,702,142,704.6 |
| 应收票据及应收账款 | 174,620,154.83 | 217,366,726.06 | 170,174,404.15 | 160,406,614.48 |
| 其中：应收票据 | 532,080.6 | - | - | - |
| 应收账款 | 174,088,074.23 | 217,366,726.06 | 170,174,404.15 | 160,406,614.48 |
| 预付款项 | 41,589,916.99 | 25,533,757.43 | 18,681,602.01 | 10,482,586.49 |
| 其他应收款合计 | 16,530,155.99 | 12,184,809.85 | 18,589,941.03 | 7,046,096.18 |
| 存货 | 404,423,005.53 | 417,320,387.48 | 401,554,754.51 | 403,610,615.09 |
| 其他流动资产 | 21,047,676.39 | 22,750,607.3 | 23,413,049.74 | 21,918,464.33 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 6,203,269,721.25 | 5,814,478,777.8 | 5,696,165,936.08 | 5,305,607,081.17 |
| 非流动资产: | | | | |
| 长期股权投资 | 16,576,602.6 | 16,670,226.02 | 16,723,552.85 | 16,776,711.52 |
| 固定资产 | 2,222,635,614.51 | 2,266,615,715.27 | 2,204,361,144.36 | 2,237,846,481.5 |
| 在建工程 | 89,551,708.5 | 75,981,770.72 | 165,151,332.02 | 166,541,809.79 |
| 生产性生物资产 | 5,433,810.85 | 5,889,576.68 | 4,073,658.37 | 4,554,372.73 |
| 使用权资产 | 5,939,456.96 | 5,566,625.58 | 1,988,979.68 | 2,123,238.61 |
| 无形资产 | 293,598,905.32 | 301,322,918.29 | 309,151,412.03 | 316,803,925.3 |
| 开发支出 | 106,209,937.04 | 94,477,752.56 | 93,517,224.52 | 92,144,094.97 |
| 长期待摊费用 | 4,811,592.45 | 5,865,751.92 | 6,184,683.99 | 7,190,882.55 |
| 递延所得税资产 | 242,661,487.49 | 271,938,140.79 | 312,276,800.22 | 358,078,120.48 |
| 其他非流动资产 | 22,140,256.47 | 16,765,557.25 | 23,753,633.97 | 22,014,192.08 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,009,559,372.19 | 3,061,094,035.08 | 3,137,182,422.01 | 3,224,073,829.53 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 9,212,829,093.44 | 8,875,572,812.88 | 8,833,348,358.09 | 8,529,680,910.7 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 243,735,576.47 | 266,523,629.79 | 255,973,214.44 | 344,029,888.6 |
| 应付账款 | 243,735,576.47 | 266,523,629.79 | 255,973,214.44 | 344,029,888.6 |
| 预收款项 | 4,853,502.52 | 4,350,841.11 | 16,268,754.88 | 3,882,684.2 |
| 合同负债 | 3,815,902.29 | 6,526,433.85 | 6,667,982.25 | 5,100,351.22 |
| 应付职工薪酬 | 24,452,329.41 | 41,797,318.03 | 38,683,913.34 | 133,984,230.83 |
| 应交税费 | 51,195,410.18 | 50,060,584.88 | 55,220,871.26 | 35,954,316.01 |
| 其他应付款合计 | 336,635,176.41 | 240,745,117.04 | 181,442,349.19 | 64,358,028.63 |
| 一年内到期的非流动负债 | 2,406,915.38 | 2,379,090.59 | 407,555.43 | 531,817.42 |
| 其他流动负债 | 68,397,330.91 | 57,761,841.03 | 39,830,765.79 | 66,590,505.46 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 735,492,143.57 | 670,144,856.32 | 594,495,406.58 | 654,431,822.37 |
| 非流动负债: | | | | |
| 租赁负债 | 3,875,876.37 | 3,235,485.25 | 1,517,414.03 | 1,479,498.27 |
| 长期应付款 | 10,122,093.41 | 17,664,219.71 | 26,849,036.55 | 36,599,821.39 |
| 递延收益 | 17,704,042.3 | 18,120,351.19 | 18,536,660.08 | 17,307,968.97 |
| 递延所得税负债 | 11,054,552.41 | 10,444,869.77 | 8,578,813.88 | 7,944,751.41 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 42,756,564.49 | 49,464,925.92 | 55,481,924.54 | 63,332,040.04 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 778,248,708.06 | 719,609,782.24 | 649,977,331.12 | 717,763,862.41 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 919,778,254 | 919,756,504 | 919,463,954 | 919,463,954 |
| 资本公积 | 1,996,600,785.93 | 1,996,681,168.14 | 1,990,162,751.84 | 1,989,597,189.13 |
| 其他综合收益 | -1,489,530.04 | -1,811,781.2 | -1,928,124.9 | -1,341,442.82 |
| 盈余公积 | 515,315,206.97 | 515,315,206.97 | 515,315,206.97 | 515,315,206.97 |
| 未分配利润 | 5,005,309,774.87 | 4,723,818,236.77 | 4,754,515,972.41 | 4,380,994,499.35 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 8,435,514,491.73 | 8,153,759,334.68 | 8,177,529,760.32 | 7,804,029,406.63 |
| 少数股东权益 | -934,106.35 | 2,203,695.96 | 5,841,266.65 | 7,887,641.66 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 8,434,580,385.38 | 8,155,963,030.64 | 8,183,371,026.97 | 7,811,917,048.29 |
| 负债和股东权益合计 | 9,212,829,093.44 | 8,875,572,812.88 | 8,833,348,358.09 | 8,529,680,910.7 |
| 公告日期 | 2024-10-25 | 2024-08-23 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |